While Viatris is a relatively new name among the pharmaceutical players, it is by no means a newcomer. The company is the result of the merger between Mylan and Upjohn, a legacy division of Pfizer. With the experience and brand legacy of two iconic powerhouses, Viatris is well-equipped to tackle the future. MIMS Doctor speaks to Jeff Bote, country manager of Viatris Malaysia, and learns a little about their direction and aspirations for the future.